<DOC>
	<DOCNO>NCT01233947</DOCNO>
	<brief_summary>AFP464 investigational agent may effective treatment cancer . The purpose study test efficacy AFP464 +/- Faslodex ER+ breast cancer patient .</brief_summary>
	<brief_title>Study AFP464 +/- Faslodex ER + Breast Cancer</brief_title>
	<detailed_description>This randomize , open-label study . Patients randomize 1:1 ratio single arm AFP464 , AFP464+Faslodex . Patients treated disease progression note .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>proven breast cancer , ER+ status ; progression aromatase inhibitor ; measurable disease evaluable disease serum CA27.29 &gt; =50 U/mL ; adequate bone marrow , liver renal function ; DLco grade 0 1 . HER2 positive , thoracic radiotherapy symptomatic pulmonary disease , brain metastasis ,</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>